Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly’s version of the drug, called Rezvoglar (insulin glargine-aglr).

A new cheaper biosimilar version of Sanofi's Lantus (insulin glargine) has been launched in the UK today, and is likely to dent sales of the blockbuster product. Lilly and Boehringer Ingelheim's ...

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

Lilly also doesn’t engage in practices that ... a competitor’s basal insulin (Lantus), at a 78% lower price.” A spokesperson for the third “big three” insulin manufacturer, Sanofi ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...

Innovator Eli Lilly, whose weight loss drug Tirzepatide ... Mankind has inlicensed Glargine insulin from Biocon, and they could leverage that sales force to market GLP-1s.